Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Eli Lilly) of abemaciclib (Verzenios) to submit evidence for the clinical and cost effectiveness of this drug in combination with endocrine therapy (ET) for the treatment of adult patients with hormone receptor (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Orozco Leal, Giovany, Armstrong, Nigel, Kernohan, Ashleigh, Ahmadu, Charlotte, Coughlan, Diarmuid, McDermott, Kevin, Duffy, Steven, O’Meara, Susan, Robinson, Tomos, Vale, Luke, Kleijnen, Jos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034868/
https://www.ncbi.nlm.nih.gov/pubmed/36952138
http://dx.doi.org/10.1007/s40273-023-01259-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034868/
https://www.ncbi.nlm.nih.gov/pubmed/36952138
http://dx.doi.org/10.1007/s40273-023-01259-6

Ejemplares similares